Pharmalot published a recent surveyconducted by Cutting Edge that looks at how much and how money is being spent by pharma companies on outcome research. It used to be getting approved was enough. Now companies need to show their product actually does something better for patients in order to increase their chances of third parties paying for the treatments.
At the 50 largest drugmakers, spending levels average $7.5 million on outcomes research. In the US, for instance, economics and outcomes research is typically being used to support 10 brands, although the 20 largest drugmakers are supporting nearly 20 brands, and the average spending per brand was $493,000. Budget changes among all companies compared with 2011 rose 42 percent, but among those who are clearly spending more, increases rose by 66 percent, on average. Small drugmakers report the largest increases at 79 percent.
What happens if you don't do outcomes research well and don't get good third party uptake? Looking at drugs like Dendreon's Provenge or HGS Benlysta might give some insight.............
Posted by Bruce Lehr Aug 24th 2012.